214 related articles for article (PubMed ID: 21088576)
1. SPAK and WNK kinases: a new target for blood pressure treatment?
Glover M; O'shaughnessy KM
Curr Opin Nephrol Hypertens; 2011 Jan; 20(1):16-22. PubMed ID: 21088576
[TBL] [Abstract][Full Text] [Related]
2. Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia.
Glover M; O'Shaughnessy KM
Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):876-84. PubMed ID: 23683032
[TBL] [Abstract][Full Text] [Related]
3. WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension.
Brown A; Meor Azlan NF; Wu Z; Zhang J
Acta Pharmacol Sin; 2021 Apr; 42(4):508-517. PubMed ID: 32724175
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice.
Nishida H; Sohara E; Nomura N; Chiga M; Alessi DR; Rai T; Sasaki S; Uchida S
Hypertension; 2012 Oct; 60(4):981-90. PubMed ID: 22949526
[TBL] [Abstract][Full Text] [Related]
5. Activation of the thiazide-sensitive Na+-Cl- cotransporter by the WNK-regulated kinases SPAK and OSR1.
Richardson C; Rafiqi FH; Karlsson HK; Moleleki N; Vandewalle A; Campbell DG; Morrice NA; Alessi DR
J Cell Sci; 2008 Mar; 121(Pt 5):675-84. PubMed ID: 18270262
[TBL] [Abstract][Full Text] [Related]
6. WNK-SPAK-NCC cascade revisited: WNK1 stimulates the activity of the Na-Cl cotransporter via SPAK, an effect antagonized by WNK4.
Chávez-Canales M; Zhang C; Soukaseum C; Moreno E; Pacheco-Alvarez D; Vidal-Petiot E; Castañeda-Bueno M; Vázquez N; Rojas-Vega L; Meermeier NP; Rogers S; Jeunemaitre X; Yang CL; Ellison DH; Gamba G; Hadchouel J
Hypertension; 2014 Nov; 64(5):1047-53. PubMed ID: 25113964
[TBL] [Abstract][Full Text] [Related]
7. Role of SPAK and OSR1 signalling in the regulation of NaCl cotransporters.
Mercier-Zuber A; O'Shaughnessy KM
Curr Opin Nephrol Hypertens; 2011 Sep; 20(5):534-40. PubMed ID: 21610494
[TBL] [Abstract][Full Text] [Related]
8. WNK4 is indispensable for the pathogenesis of pseudohypoaldosteronism type II caused by mutant KLHL3.
Susa K; Sohara E; Takahashi D; Okado T; Rai T; Uchida S
Biochem Biophys Res Commun; 2017 Sep; 491(3):727-732. PubMed ID: 28743496
[TBL] [Abstract][Full Text] [Related]
9. Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT.
Glover M; Zuber AM; O'Shaughnessy KM
Cardiovasc Ther; 2011 Feb; 29(1):68-76. PubMed ID: 21167012
[TBL] [Abstract][Full Text] [Related]
10. SPAK deficiency corrects pseudohypoaldosteronism II caused by WNK4 mutation.
Chu PY; Cheng CJ; Wu YC; Fang YW; Chau T; Uchida S; Sasaki S; Yang SS; Lin SH
PLoS One; 2013; 8(9):e72969. PubMed ID: 24039833
[TBL] [Abstract][Full Text] [Related]
11. Renal sodium and magnesium reabsorption are not coupled in a mouse model of Gordon syndrome.
van Megen WH; Grimm PR; Welling PA; van der Wijst J
Physiol Rep; 2018 Jul; 6(14):e13728. PubMed ID: 30030908
[TBL] [Abstract][Full Text] [Related]
12. Effect of heterozygous deletion of WNK1 on the WNK-OSR1/ SPAK-NCC/NKCC1/NKCC2 signal cascade in the kidney and blood vessels.
Susa K; Kita S; Iwamoto T; Yang SS; Lin SH; Ohta A; Sohara E; Rai T; Sasaki S; Alessi DR; Uchida S
Clin Exp Nephrol; 2012 Aug; 16(4):530-8. PubMed ID: 22294159
[TBL] [Abstract][Full Text] [Related]
13. Structural development of N-(4-phenoxyphenyl)benzamide derivatives as novel SPAK inhibitors blocking WNK kinase signaling.
Fujii S; Kikuchi E; Watanabe Y; Suzuyama H; Ishigami-Yuasa M; Mori T; Isobe K; Uchida S; Kagechika H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127408. PubMed ID: 32738993
[TBL] [Abstract][Full Text] [Related]
14. WNK signalling pathways in blood pressure regulation.
Murthy M; Kurz T; O'Shaughnessy KM
Cell Mol Life Sci; 2017 Apr; 74(7):1261-1280. PubMed ID: 27815594
[TBL] [Abstract][Full Text] [Related]
15. Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone.
Chiga M; Rai T; Yang SS; Ohta A; Takizawa T; Sasaki S; Uchida S
Kidney Int; 2008 Dec; 74(11):1403-9. PubMed ID: 18800028
[TBL] [Abstract][Full Text] [Related]
16. Exploring the intricate regulatory network controlling the thiazide-sensitive NaCl cotransporter (NCC).
Dimke H
Pflugers Arch; 2011 Dec; 462(6):767-77. PubMed ID: 21927811
[TBL] [Abstract][Full Text] [Related]
17. Phenotypes of pseudohypoaldosteronism type II caused by the WNK4 D561A missense mutation are dependent on the WNK-OSR1/SPAK kinase cascade.
Chiga M; Rafiqi FH; Alessi DR; Sohara E; Ohta A; Rai T; Sasaki S; Uchida S
J Cell Sci; 2011 May; 124(Pt 9):1391-5. PubMed ID: 21486947
[TBL] [Abstract][Full Text] [Related]
18. Regulatory control of the Na-Cl co-transporter NCC and its therapeutic potential for hypertension.
Meor Azlan NF; Koeners MP; Zhang J
Acta Pharm Sin B; 2021 May; 11(5):1117-1128. PubMed ID: 34094823
[TBL] [Abstract][Full Text] [Related]
19. Cotransporters, WNKs and hypertension: an update.
Flatman PW
Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):186-92. PubMed ID: 18277153
[TBL] [Abstract][Full Text] [Related]
20. Role of the WNK-activated SPAK kinase in regulating blood pressure.
Rafiqi FH; Zuber AM; Glover M; Richardson C; Fleming S; Jovanović S; Jovanović A; O'Shaughnessy KM; Alessi DR
EMBO Mol Med; 2010 Feb; 2(2):63-75. PubMed ID: 20091762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
